SCHEMBL20160445

SCHEMBL20160445

COC1CCC(C(=O)N2C3CC2CN(C)C3)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.35
HSD11B1 P28845 2/20 0.34
MAPT P10636 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
CNR1 P21554 1/20 0.34
HTT P42858 1/20 0.33
CHRNB2 P17787 2/20 0.33
CHRNA3 P32297 2/20 0.33
CHRNA4 P43681 2/20 0.33
CHRNB3 Q05901 2/20 0.33
CHRNA6 Q15825 2/20 0.33
ACACB O00763 1/20 0.32
ACACA Q13085 1/20 0.32
RECQL P46063 1/20 0.32
IDH1 O75874 2/20 0.31
WNT1 P04628 1/20 0.31
GSK3B P49841 1/20 0.31
DYRK1A Q13627 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20160448 0.88 MAPT (0.42) MAPTCNR1HTTCHRNB2CHRNA3
SCHEMBL20071313 0.87 RET (0.34) RETNPC1RAB9AKMT2ACNR1
SCHEMBL20154459 0.83 RET (0.34) RETHSD11B1MAPTNPC1RAB9A
SCHEMBL21159142 0.83 RET (0.36) RETHSD11B1MAPTNPC1RAB9A
SCHEMBL20071306 0.83 HSD11B1 (0.35) RETHSD11B1MAPTNPC1RAB9A
SCHEMBL20071309 0.81 MAPT (0.41) RETMAPTCNR1HTTCHRNB2
SCHEMBL21695514 0.81 RECQL (0.48) HSD11B1CNR1HTTCHRNB2CHRNA3
SCHEMBL20071307 0.81 RECQL (0.48) HSD11B1MAPTCNR1HTTCHRNB2
SCHEMBL20071305 0.80 RECQL (0.52) HSD11B1KMT2ACNR1CHRNB2CHRNA3
SCHEMBL13265396 0.79 MAPT (0.43) MAPTCNR1HTTCHRNB2CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2024-02-29 US disclosed
US-20210186959-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2021-06-24 US disclosed
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF RET 1/4885HSD11B1 2343/4885MAPT 1769/4885
US-20210186959-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF RET 1/4885HSD11B1 2343/4885MAPT 1769/4885
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF RET 1/4885HSD11B1 2343/4885MAPT 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.